PCAOB Deficiency Tracker
← Back to Explorer

Gaveglio Aparicio y Asociados S. Civil de R.L.

Peru · PricewaterhouseCoopers International Limited · Triennially Inspected

Inspection year
2020
Report date
08-Apr-2022
PCAOB release
104-2022-111
Audits reviewed
3
Audits w/ Part I.A deficiencies
2
Part I.A deficiency rate
67%
Part I.A deficiencies
4
Part I.B deficiencies
3
Report
View PDF ↗

Deficiencies (4)

Grouped by issuer and in the same order as the PCAOB report, so each item ties back directly to the source.

Issuer A3 deficiencies

#AreaDeficiencyStandardFlags
1RevenueThe issuer recognized revenue in accordance with the terms and conditions of contractual arrangements with customers which were entered into the billing systems and used to create sales invoices and record revenue. The firm did not identify and test any controls to ensure that customers were invoiced and the related revenue was recognized in accordance with the contractual terms and conditions. Further the firm did not identify and test any controls over the initial entry of pricing data into the issuer's billing systems. (AS 2201.39)
ICFR audit only
AS 2201.39
2RevenueThe firm selected for testing a control that consisted of the issuer's review of month-to-month revenue variances. The firm did not evaluate the review procedures that the control owners performed including the procedures to identify items for follow up and the procedures to determine whether those items were appropriately resolved. (AS 2201.42 and .44)
ICFR audit only
AS 2201.42; AS 2201.44
3Long-Lived AssetsThe firm did not identify and test any controls over the identification of impairment indicators with respect to property plant and equipment ('PP&E'). Further the firm did not identify and test any controls over the determination of depreciation expense related to certain PP&E. (AS 2201.39)
ICFR audit only
AS 2201.39

Issuer B1 deficiency

#AreaDeficiencyStandardFlags
1Investment SecuritiesThe issuer used various external pricing sources to determine the fair value of certain investments. The firm did not test the fair value of these investments beyond comparing their fair value to (1) pricing data that the firm obtained from the same sources used by the issuer or (2) a pricing report prepared by the issuer. (AS 2502.26 and .28)
Financial statement audit only
AS 2502.26; AS 2502.28